Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$5.85 USD
+0.44 (8.13%)
Updated Sep 22, 2025 03:59 PM ET
After-Market: $5.86 +0.01 (0.17%) 5:06 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KPTI 5.85 +0.44(8.13%)
Will KPTI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KPTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KPTI
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
KPTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
Other News for KPTI
New Downtrend appears for KPTI after 5.58% move
Is KPTI gaining bullish strength? Non-ADX 1,2,3,4 Bullish shows up after tumbling 5.76%
KPTI's price falls by 2.88% on September 17, though its technical setup remains stable.
KPTI forms NR7 on September 16
KPTI forms 20 Day Moving Average Resistance on September 15